Rift valley fever future or investigational therapies: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 2: Line 2:
{{Rift valley fever}}
{{Rift valley fever}}
{{CMG}}{{AE}} {{AAH}}
{{CMG}}{{AE}} {{AAH}}
 
==Overview==
There are no first line drugs recommended for treatment of [[Rift valley fever]] as it is primarily a viral disease. [[Ribavirin]] showed promise initially by reducing the viral load, but was later found to be associated with adverse affects. Many vaccines are under the process of development, some of which may be used in both animals and humans. Until such vaccines are available, the public health departments in the endemic areas should consider using the available vaccines to keep the disease in check.
==Future or investigational therapies==
*Many [[Vaccine|vaccines]] are under investigational testing for use in livestock.<ref>Njenga MK, Njagi L, Thumbi SM, et al. Randomized controlled field trial to assess the immunogenicity and safety of rift valley fever clone 13 vaccine in livestock. PLoS neglected tropical diseases. 2015 Mar;9(3):e0003550.</ref>
*Many [[Vaccine|vaccines]] are under investigational testing for use in livestock.<ref>Njenga MK, Njagi L, Thumbi SM, et al. Randomized controlled field trial to assess the immunogenicity and safety of rift valley fever clone 13 vaccine in livestock. PLoS neglected tropical diseases. 2015 Mar;9(3):e0003550.</ref>
*Some vaccines being developed may be safe to use in both animals and humans.
*Some vaccines being developed may be safe to use in both animals and humans.

Revision as of 16:32, 17 July 2021

Rift valley fever Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Rift valley fever from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Rift valley fever future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Rift valley fever future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Rift valley fever future or investigational therapies

CDC on Rift valley fever future or investigational therapies

Rift valley fever future or investigational therapies in the news

Blogs on Rift valley fever future or investigational therapies

Directions to Hospitals Treating Rift valley fever

Risk calculators and risk factors for Rift valley fever future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Aakash Hans, MD[2]

Overview

There are no first line drugs recommended for treatment of Rift valley fever as it is primarily a viral disease. Ribavirin showed promise initially by reducing the viral load, but was later found to be associated with adverse affects. Many vaccines are under the process of development, some of which may be used in both animals and humans. Until such vaccines are available, the public health departments in the endemic areas should consider using the available vaccines to keep the disease in check.

Future or investigational therapies

  • Many vaccines are under investigational testing for use in livestock.[1]
  • Some vaccines being developed may be safe to use in both animals and humans.
  • Ribavirin showed promise in rodent models but was stopped after development of neurological symptoms in some of the patients it was administered during the RVF outbreak in Saudi Arabia in the year 2000. [2]
  • Significant financial investment would be required to undergo vaccine development on a large scale.

References

  1. Njenga MK, Njagi L, Thumbi SM, et al. Randomized controlled field trial to assess the immunogenicity and safety of rift valley fever clone 13 vaccine in livestock. PLoS neglected tropical diseases. 2015 Mar;9(3):e0003550.
  2. Bird BH, Reynes JM, Nichol ST. Rift Valley Fever. In: Magill AJ, Strickland GT, Maguire JH, Ryan ET, Solomon T, editors. Hunter’s Tropical Medicine and Emerging Infectious Disease. 9. Elsevier Health Sciences; 2012.

Template:WH Template:WS